Neoadjuvant Nivolumab/Relatlimab Induces High Rates of Pathologic Responses in Patients with Locally Advanced MMR-deficient Colon Cancer By Ogkologos - November 22, 2024 756 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NICHE-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR In memory of Dame Deborah James June 29, 2022 Analysis Shows Women with High Breast Cancer Recurrence Scores Benefit from... October 24, 2019 Nivolumab and Ipilimumab Effective against Melanoma That Has Spread to the... September 20, 2018 New Research in Treating Non-Hodgkin Lymphoma and Predicting the Risk of... January 26, 2023 Load more HOT NEWS 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or... Researchers Discover Way to Help Immunotherapy Better Target Solid Tumors Like... FDA Approves Carfilzomib and Daratumumab with Dexamethasone for Multiple Myeloma
